Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Doccoleon Sep 24, 2020 11:06am

225 Views

Post# 31611251

RE:RE:RE:I am of the opinion

My biggest problem-

I don't think this CEO knows what he is doing. He is constantly driving the price down on the stock. The market is hip to a reverse split then a raise. Also, regardless of what you all say....this is still at high risk and still a phase 2 company. Don't count your chickens before they're hatched. I like the science, have lil faith in CEO.

full disclosure- I hold a significant position and will not add now because the future raise and terrible looking chart.

Bullboard Posts

Bombardier delivers Global 6500 aircraft to U.S. Army